Take Homes in Wet AMD

Take Homes in Wet AMD

Source:

Singh R. Baseline factors influencing diabetic macular edema (DME) resolution after intravitreal aflibercept injection (IAI) or laser treatment in VISTA/VIVID. Presented at: American Society of Retina Specialists meeting; Oct. 8-12, 2021; San Antonio.

Disclosures: Singh reports consulting for Alcon, Genentech, Gyroscope, Novartis and Regeneron.
October 27, 2021
1 min watch
Save

VIDEO: No link between time to DME resolution, HbA1c

Source:

Singh R. Baseline factors influencing diabetic macular edema (DME) resolution after intravitreal aflibercept injection (IAI) or laser treatment in VISTA/VIVID. Presented at: American Society of Retina Specialists meeting; Oct. 8-12, 2021; San Antonio.

Disclosures: Singh reports consulting for Alcon, Genentech, Gyroscope, Novartis and Regeneron.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Rishi P. Singh, MD, of Cleveland Clinic, discussed post hoc analysis results from the VISTA and VIVID studies, which he presented at the ASRS meeting.

In a video interview, Singh talked about the baseline factors, such as glucose control, that may predict the faster or slower resolution of diabetic macular edema.

“We did not see a relationship between the time to DME resolution and the hemoglobin A1c, which I think gives a lot of clinicians some surety about explaining to patients really the finer points of how long it will take therapy to get to a stable resolution of DME,” Singh told Healio. “It just informs patients about what their expectations may meet with regards to DME therapy in real-world clinical practice.”